CanAg® Glypican-3 EIA

The CanAg Glypican-3 EIA is a manual enzyme immunometric assay for the quantitative determination of Glypican-3 in human serum.The assay is indicated for use as an aid in the diagnosis of hepatocellular carcinoma (HCC) . The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.The CanAg Glypican-3 EIA is a solid-phase, non-competitive 2-step immunoassay based upon the direct sandwich technique using two mouse monoclonal antibodies directed against two epitopes in the N-terminal protein core of Glypican-3.Glypican-3 has been shown to be expressed early in the development of HCC1and is a serum biomarker that in combination with AFP and PIVKA-II has demonstrated high sensitivity and specificity for hepatocellular carcinoma2.ReferencesYamauchi et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005 Dec;18 (12) :1591-8.Xu et al. Performance of Serum Glypican 3 in Diagnosis of Hepatocellular Carcinoma: A meta-analysis. Ann Hepatol. : 58-67.Jan-Feb 2019;18 (1)